| Literature DB >> 31703334 |
Stephanie Aguero1, Raphaël Terreux1,2.
Abstract
Explosives molecules have been widely used since World War II, leading to considerable contamination of soil and groundwater. Recently, bioremediation has emerged as an environmentally friendly approach to solve such contamination issues. However, the 1,3,5,7-tetranitro-1,3,5,7-tetrazocane (HMX) explosive, which has very low solubility in water, does not provide satisfying results with this approach. In this study, we used a rational design strategy for improving the specificity of the nitroreductase from E. Cloacae (PDB ID 5J8G) toward HMX. We used the Coupled Moves algorithm from Rosetta to redesign the active site around HMX. Molecular Dynamics (MD) simulations and affinity calculations allowed us to study the newly designed protein. Five mutations were performed. The designed nitroreductase has a better fit with HMX. We observed more H-bonds, which productively stabilized the HMX molecule for the mutant than for the wild type enzyme. Thus, HMX's nitro groups are close enough to the reductive cofactor to enable a hydride transfer. Also, the HMX affinity for the designed enzyme is better than for the wild type. These results are encouraging. However, the total reduction reaction implies numerous HMX derivatives, and each of them has to be tested to check how far the reaction can' go.Entities:
Keywords: HMX; High Energy Molecules; bioremediation; flavoprotein; molecular dynamics; nitroreductase; protein design; substrate specificity
Year: 2019 PMID: 31703334 PMCID: PMC6888211 DOI: 10.3390/ijms20225556
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Two-dimensional chemical structures of (a) 2,4,6-trinitrotoluene (TNT), (b) hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX), and (c) 1,3,5,7-tetranitro-1,3,5,7-tetrazocane (HMX).
Figure 2(a) Kinetic mechanism of the nitroreductase (NR) from Enterobacter Cloacae. NR is oxygen insensitive and involves two electron transfers at each reduction step. (b) Atom numbering of oxidized form of flavin mononucleotide (FMN). (c) FMN and reduced form of flavin mononucleotide (FMNH2) structures.
Figure 3Pipeline/workflow of the study.
Figure 4Target Residues for Design Trials. All the residues displayed in yellow are included in the resfile. FMNH2 cofactor is displayed in green, and HMX molecule in blue.
Figure 5Relative Amino Acid Proportions at Positions 68, 70, 120, 123, and 125 in Low-Energy Structures. The relative size of each letter indicates their frequency in the sequences, and the total height of the letters shows the information content of the position, in bits.
Figure 6The Molecular Operating Environment software (MOE) Ligand Interactions application allows for the visualization of the protein active site in complex with HMX, in diagrammatic form. The diagram shows solvent interactions, H-bonds and surface of exposure. (a) Wild Type NR and HMX; (b) Mutant NR and HMX.
Figure 7Mutated Residues after Design Trials. All the positions displayed in yellow were included in the resfile. FMNH2 cofactor is displayed in green and HMX molecule in blue. Non-mutated residues implied in H-bonds with the HMX are in cyan.
Table of free-energy calculation of NR/ligand complex. MMGBSA is calculated as a sum of a conformational energy terms supplemented with a solvation free-energy term calculated using continuum electrostatics.
| Complex NR/HMX | mmGBSA (kcal/mol) |
|---|---|
| Wild Type NR/p-NBA | −15.2117 |
| Wild Type NR/HMX | −11.8261 |
| Mutant NR/HMX | −29.0704 |
Figure 8Root Mean Square Deviation (RMSD) plots over time of every simulation of both WT and mutant NR. (1) RMSD plots of WT protein in complex with 4NB. (a) Protein, (b) cofactor FMNH2, and (c) 4NB. (2) RMSD plots of WT protein in complex with HMX. (a) Protein, (b) cofactor FMNH2, and (c) HMX. (3) RMSD plots of mutant protein in complex with HMX. (a) Protein, (b) cofactor FMNH2, and (c) HMX. (4) RMSD plots of relaxed mutant protein without HMX (a) Protein, (b) cofactor FMNH2.
Figure 9Average distance between each atom of oxygen from HMX and atom N5 of the FMNH2 in (a) the WT and (b) the mutant NR.
Figure 10NADPH bound into the active site of the mutant NR. Protein backbone are shown in grey. Residue interacting with NADPH is shown as sticks. FMN is shown in green. The distance between the N5 of the flavin and the transferable H of NADPH is depicted.
HMX derivative molecules.
| HMX Derivative Molecule | Name |
|---|---|
|
| 1,3,5,7-tetranitro-1,3,5,7-tetrazocane |
|
| 1,3,5-trinitro-7-nitroso-1,3,5,7-tetrazocane |
|
| 1,3-ditrinitro-5,7-dinitroso-1,3,5,7-tetrazocane |
|
| 1,5-ditrinitro-3,7-dinitroso-1,3,5,7-tetrazocane |
|
| 1-Nitro-3,5,7-trinitroso-1,3,5,7-tetrazocane |
|
| 1,3,5,7-tetranitroso-1,3,5,7-tetrazocane |
|
| N-(3,5,7-trinitroso-1,3,5,7-tetrazocan-1-yl) hydroxylamine |
|
| N-[3-(hydroxyamino)-5,7-dinitroso-1,3,5,7-tetrazocan-1-yl] hydroxylamine |
|
| N-[5-(hydroxyamino)-3,7-dinitroso-1,3,5,7-tetrazocan-1-yl] hydroxylamine |
|
| N-[(3,5-bis(hydroxyamino)-7-nitroso-1,3,5,7-tetrazocan-1-yl] hydroxylamine |
|
| N-[3,5,7-tris(hydroxyamino)-1,3,5,7-tetrazocan-1-yl] hydroxylamine |
|
| N1,N3,N5-trihydroxy-1,3,5,7-tetrazocane-1,3,5,7-tetramine |
|
| N1,N3-dihydroxy-1,3,5,7-tetrazocane-1,3,5,7-tetramine |
|
| N1,N5-dihydroxy-1,3,5,7-tetrazocane-1,3,5,7-tetramine |
|
| N1-hydroxy-1,3,5,7-tetrazocane-1,3,5,7-tetramine |